2008;101:1112 8. 982. Adabag AS, Ishani A, Bloomfield HE, et al. efficacy of N-acetylcysteine in preventing renal injury after heart surgery: a sys- tematic review of randomized trials. Eur Heart J. 2009;30:1910 7. 983. Amar D, Fleisher M. Diltiazem treatment does not alter renal function after thoracic surgery. Chest. 2001;119:1476 9. 984. Caimmi PP, Pagani L, Micalizzi E, et al. Fenoldopam for renal pro- tection in patients undergoing cardiopulmonary bypass. J Cardiothorac Vasc Anesth. 2003;17:491 4. 985. Cogliati AA, Vellutini R, Nardini A, et al. Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. J Cardiothorac Vasc Anesth. 2007;21:847 50. 986. Davis RF, Giesecke NM. Hemodilution and priming solutions. In: Gravlee GP, Davis RF, Kurusz M, Utley JR, editors. Cardiopulmonary Hillis et al 2011 ACCF/AHA CABG Guideline e723 Bypass: Principles and Practice. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000:186 196. 987. El-Hamamsy I, Stevens LM, Carrier M, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg. 2007;133:7 12. 988. Fansa I, Gol M, Nisanoglu V, et al. Does diltiazem inhibit the inflam- matory response in cardiopulmonary bypass? Med Sci Monit. 2003;9: PI30 6. 989. Fischer UM, Tossios P, Mehlhorn U. Renal protection by radical scavenging in cardiac surgery patients. Curr Med Res Opin. 2005;21: 1161 4. 990. Friedrich JO, Adhikari N, Herridge MS, et al. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142:510 24. 991. Haase M, Haase-Fielitz A, Bagshaw SM, et al. Phase II, randomized, controlled trial of high-dose N-acetylcysteine in high-risk cardiac surgery patients. Crit Care Med. 2007;35:1324 31. 992. Ip-Yam PC, Murphy S, Baines M, et al. 